Gordon Stein, CFO of CleanTech Lithium, explains why CTL acquired the 23 Laguna Verde licenses. Watch the video here.
Ahem, just to put some needed context here, norm medical diagnostics p/e range from 15-30, NCYT is current operating under 4. Its really not that hard, ok, longevity issues come into play as at the moment they are a covid play, but without doubt they've shown how they react to issues should give confidence. It will take time to get their p/e to industry standard, but right now its a fecking joke, I would expect a p/e of at least double of what they currently have, and have full confidence come Monday some sense of normality will resume. SP will be £20 within a month if they land any major contracts - ps they will.
https://twitter.com/PrimerdesignLtd/status/1355061613024436225
"Don’t celebrate yet!! We got more work to do still."
Hint hint hint
https://twitter.com/PrimerdesignLtd/status/1354466532269715456
Confirmation of value on the Unicef Ukraine contract, with primerdesign.
https://reliefweb.int/report/ukraine/world-bank-and-unicef-deliver-12-million-covid-19-pcr-tests-ukraine-enuk
Airline boy - yep it does they tweeted about it earlier in the week.
https://twitter.com/PrimerdesignLtd/status/1338526890957615105
"A new variant of coronavirus has been identified in the southeast of England. With our kits continuing to show 100% sensitivity in this new strain, we have you covered"
Earth7000 - that's not the biggest tender and less likely for NCYT as its for LFT (unless NCYT have a LFT test up their sleeve which wouldn't surprise me). The biggest contract is 22b. There are two of them. Please see here
https://bidstats.uk/tenders/?q=national+microbiological+framework.
Look CEO's are always inside. He will be well aware of all the sales happening every day, to which we aren't privy. He knows current demand for their tests and will have a very good idea of future demand. He will be aware of the tenders they've applied for and are up for grabs - the tenders may be signed off next week who knows - but they aren't a certainty - so that's all the Nomad will require. Just because the CEO bought it doesn't mean a large contract win won't happen next week - as that's out of the CEO's control. What it does show is huge confidence.
Routy - the problem with big II's is they like to see ££££ before diving in. Risk adverse. When you're putting in millions or hundreds of thousands you often don't need the big percentage winners to make your money. Your money works for itself. Its different to us pig herders down in the muck of aim, we look for than one than can take us to that hallowed ground. But once in a blue moon the two meet, the pig herders and the big boys all want a slice of that same warm apple pie that is NCYT. They've spotted an opportunity to make more than there normal dividend return and 10-20% yearly increase, whilst us lucky AIM'ers got in early. No wonder we know more than them, we've been researching the ass out of this and its potential for 8 months, and know it inside out and its potential, it doesn't often happen like this. A couple of stocks a year go well, but one this well run with the right products at exactly the right time is generational. Enjoy holders. Big contracts coming, rerate will continue.
Casshy - you need to understand what their ev/ebitda is - its low. Very low. Its still undervalued, most people just see huge rise and think it can't go up further, it can when its generating as much revenue at high margins as it is. Its still undervalued by some distance.
See this tweet from the director of testing
https://twitter.com/BWCHBoss/status/1317175370039394304
"Absolutely. We need PCR no matter what and huge investments have been made in NHS Testing over recent weeks. A doubling of PCR capacity, plus DNA Nudge, Samba II and Primerdesign all happening now"
It could be anyone really. The fact that they've already bought millions and are being used in hospital - well that rules out most who are still in development. So that leaves NCYT and Abbott. However the 15 min part makes me believe its Abbotts Panbio rapid test - which the US use. There was an order for £45m recently for these on bidstats. However its sensitivity isn't great and has been criticised in the US recently - which wait for it means that negative tests possible will have to be followed up by a more accurate PCR test. However I'm imagine there are other tests out there on the horizon also that Boris was referring to, and of those we don't have a clue - ODX, AVCT, NCYT or insert private company here. We know NCYT are developing new tests, and GM never shouts out about them until they're CE marked and ready to go, so who knows he could have something up his sleeve, quite probable really. But in reality you'll need a combination of all these sorts of tests (rapid, antigen, molecular, antibody etc etc) to get ontop of the pandemic.
Just remember Numis constantly upgrade broker notes as they go along (unless they are trying to get a placing away see SNG) - at GGP in April they upgraded their target from 6p to 12p. What is GGP now, double that at 24p.
https://twitter.com/ConnetableD/status/1316455227361505280
"French updates for TESTING
(Based on president last update).
1.2 - 1.4M tests/ per week. Aiming for way more as they are still too many people waiting for test everyday. Long Q to get tested. An average 2 days to get results due to lack of technology."
Also new tests to be ordered to summer of 2021...
Step forward NCYT.........
Yep wouldn't be surprised they didn't handle the tests the right way, the same happened back in April/May by some study on Genesig which was quickly rebuked by primerdesign, and turned out they weren't following the correct procedures.